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higher than for each of the other treatment strategies but this was likely to have been 
due to the selection of an elderly population in this trial rather than a result of the 
intervention. CONCLUSIONS: The large uncertainty around the potential beneﬁ ts of 
DOT strategies prohibits a conclusive statement regarding their cost-effectiveness in 
comparison to SAT. 
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LIBYAN POPULATION IN NORTH EAST LIBYA
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OBJECTIVES: To evaluate the knowledge of North Eastern Libyan population with 
regards to the etiology and treatment of tuberculosis (TB). METHODS: A cross sec-
tional study was undertaken in 2009. A pre-validated questionnaire was sent to 1400 
residents residing in ﬁ ve cities of North East Libya. At the end of the study a total of 
1000 questionnaire was collected. Questionnaire includes questions related to respon-
dent’s demographics, general knowledge, transmission, diagnosis, risk factors, treat-
ment and prevention of TB. All data was analyzed using SPSS version 15.00 Software 
package (SPSS Inc, Chicago, IL, USA) Chi-square test and one-way ANOVA were 
used as whenever appropriate, P-value less than 0.05 was considered signiﬁ cant. 
RESULTS: Almost all subjects (n = 965, 96.5%) in this study had heard about TB. 
The main sources of knowledge were television (n = 447, 44.7%), health workers (n 
= 242, 24%) and family members (n = 189, 19%). Majority of the respondents were 
Libyans (n = 883, 88.3%). Fifty percent of the respondents were males. For the 
purpose of this research the maximum score of the knowledge which can be obtained 
by any respondent is 23. Assessment of knowledge score reveals that the mean knowl-
edge score was signiﬁ cantly higher among Libyans (11.7 ± 3.8) than non Libyans (9.7 
± 4.7, t = 26.13), (P < 0.001). In addition those respondents with tertiary educations 
scored signiﬁ cantly higher knowledge score (11.8 ± 3.5) compared to those of inter-
mediate (11.6 ± 4.4) and illiterate (7.7 ± 5.5), [F = 19.34, P = 0.001]. No signiﬁ cant 
differences between the demographic variables and knowledge score. CONCLU-
SIONS: The present study ﬁ ndings suggested that the level of knowledge about TB 
among residents in Libya was low. Therefore, there is a need for massive health educa-
tion campaign to be undertaken by policymakers in order to improve the population’s 
knowledge toward TB. 
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OBJECTIVES: To determine the incidence of zoster-associated symptoms, as well as 
the impact of zoster on pain, quality of life, work loss, health-care utilization and 
direct health-care costs among 180 Thai patients seeking medical care for herpes 
zoster. METHODS: Study design: prospective observational study conducted in seven 
hospitals in Bangkok and vicinity, Thailand Study population: patients recently diag-
nosed herpes zoster, and meeting at least one other criterion, as follows: aged ≥50 
years; aged ≥20 years with HIV-infection or receiving chemotherapy. All patients were 
scheduled for ﬁ ve visits (i.e., at Day1, Day7, Month1, Month3, Month 6) for question-
naire based interview to determine zoster-associated pain (Zoster Brief Pain Inventory 
questionnaire), quality of life (EUROQOL 5-dimension questionnaire), work and 
productivity (multi-response questionnaire), and health-care utilization and cost. Sta-
tistical analysis: Descriptive statistics and Spearman rank correlation coefﬁ cients were 
used. RESULTS: Of 180 patients, whose mean (SD) age was 58.9 (13.82) years, 138 
(76.7%), 34 (18.9%), and 8 (4.4%) were age ≥50 years, HIV-infected and immuno-
suppressed, respectively. Thirteen (7.2%) and 35 (20.6%) patients had zoster oph-
thalmicus and post-herpetic neuralgia (pain that persisted beyond 3 months of illness), 
respectively. Peak QoL lost was observed during the ﬁ rst week of study and declined 
thereafter. Correlations between worst-pain scores and QoL were moderately high, r 
= 0.54. Of those 77 working patients, 57 reported that they were absent from work, 
either entired day or part of day, during zoster illness. Thirty patients reported sick 
leave and the median number of days off was 5.5 (1–52) days. Most patients required 
only two OPD visits for zoster illnesses. Other health-care services requirement 
included emergency-room visits (n = 2), ambulance services (n = 3), or hospital admis-
sions (n = 7). The mean (SD) direct health-care cost was 3083.39 (5047.03) Thai Baht. 
CONCLUSIONS: Herpes zoster causes a signiﬁ cant burden among those who develop 
it. 
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OBJECTIVES: QALY weights for the EQ-5D are typically obtained through time 
trade-off (TTO) surveys using a sub-set (n = 17 or n = 43) of the 243 health states. 
Discrete choice experiments (DCEs) are a potentially more ﬂ exible approach. We 
explore the development of EQ-5D algorithms based on both approaches and the 
impact of selection of health states in each. METHODS: We explore experimental 
designs for the TTO and DCE approaches via, respectively, a simulation study and a 
pilot study. An on-line panel sample (n = 1000) completed the DCE. Each choice set 
presented two health proﬁ les (EQ-5D state and survival duration), and death. A popu-
lation sample (n = 417) completed a computer based TTO task and the DCE. The 
TTO incorporated 198 plausible health states. Respondents were randomly assigned 
to value 11 health states and the worst health state. Separate models were estimated 
for the DCE and the TTO. RESULTS: Results of the DCE pilot suggest that different 
experimental designs lead to differences in both the mean and variance of parameter 
estimates. There is a loss of statistical efﬁ ciency arising from using a reduced set of 
health states. The simulation study demonstrated that many interaction effects are not 
estimable from a TTO using only 43 health states. Models were estimated based on 
the functional form for the published algorithm for the EQ-5D, and allowing for 
interaction terms. While relatively few interaction terms are signiﬁ cant, comparison 
tests demonstrate that inclusion of interaction terms improves the ﬁ t of the model. 
CONCLUSIONS: Both approaches are broadly consistent with previously published 
EQ-5D algorithms, with some important differences. DCEs allows exploration of 
interactions between health states and duration that cannot be estimated with the TTO 
approach. In both approaches a design that allows for more extensive coverage of the 
EQ-5D space is appropriate. 
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OBJECTIVES: The identiﬁ cation of health care-associated infections (HAIs) is a neces-
sary ﬁ rst step for elucidating infection patterns and evaluating control measures. While 
the potential advantages to using administrative data for this purpose are recognized, 
previous attempts have proved unsuccessful. We have developed a novel method of 
HAI identiﬁ cation based on a series of criteria involving antibiotic utilization patterns 
available in administrative data. The objective of this study was to validate the accu-
racy of our HAI identiﬁ cation method using comparative analyses with chart review-
based identiﬁ cation. METHODS: We retrospectively and contemporaneously 
identiﬁ ed HAIs in 584 gastrectomy patients admitted to four Japanese hospitals (A~D) 
using both our method and chart reviews. Chart review analysis was based on CDC 
criteria for nosocomial infections. The accuracy of our method was tested using 
Cohen’s Kappa coefﬁ cient to quantify the non-random agreement between the two 
methods, as well as sensitivity, speciﬁ city, positive predictive value (PPV) and negative 
predictive value (NPV). RESULTS: Overall HAI incidence was 21.6% based on chart 
review identiﬁ cation. Cohen’s Kappa coefﬁ cient was 0.78, and sensitivity and speciﬁ c-
ity were 0.93 and 0.91, respectively. PPV was 0.75 and NPV was 0.98. CONCLU-
SIONS: These results indicate that our method of identiﬁ cation has high accuracy, 
and may be used to estimate HAIs in large populations of patients at the hospital level 
and above. While the NPV was observed to be higher than the PPV, the relatively low 
prevalence of HAI incidence may have inﬂ uenced this result. It is important to note 
that this method was not designed to pinpoint individual infections, but rather to 
identify identiﬁ cations in a large number of patients using administrative data with a 
far higher accuracy than previously available. Therefore, our method has applications 
for HAI identiﬁ cation in large groups of patients, elucidating HAI patterns and trends, 
downstream economic evaluations and multi-institutional comparisons. 
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BACKGROUND: Budget impact analysis was required for new drugs listing applica-
tion to the National Health Insurance (NHI) in Taiwan over the last decade. However, 
a working model has not been proposed until now. OBJECTIVES: To provide a simple 
framework and working tool to estimate the likely ﬁ nancial impact to NHI due to the 
submitted new drug. METHODS: To estimate the potential 5-year ﬁ nancial impact 
annually if a new drug was reimbursed, proposed framework starts with the size of 
patient population and potential claim amount of existing drugs that the new drug is 
going to target, and taking into account the clinical position and usage of the new 
relative to the existing drugs. A simple working tool by using Excel spreadsheet was 
developed accompanying the framework. Only nine cells need to be input. They are 
grouped into three parts: 1) predicted annual number of new patients receiving new 
drug; 2) treatment duration; and 3) drug cost. The ﬁ rst part should reference to local 
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epidemiology of the speciﬁ c disease, the adoption and diffusion rate of new drug, etc. 
Drug cost is expressed as the monthly cost of new and/or existing drugs. Treatment 
duration is the average months of patient remained on new and/or existing drugs 
which could be derived from clinical trials or clinical observations. Person-time on 
treatment is calculated by multiplying (1) and (2) and be allocated to respective budget 
year, then multiple (3) to obtain the annual cost of new and/or existing treatment. 
The net ﬁ nancial impact is the annual cost difference between new and existing treat-
ment. CONCLUSIONS: The framework is simple and ﬂ exible, feasible for most new 
drug applications to estimate likely ﬁ nancial impact. It has been adopted by recently 
revised new drug reimbursement application form of NHI. The working tool is freely 
available as an option for calculation. 
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OBJECTIVES: The objectives of this study were to develop the relative value units 
(RVUs) and unit costs of hospital health services employing the RVU method for 
economic evaluation in Thailand. METHODS: The RVUs were developed by using 
the objective data method based on the reimbursable price list of the Civil Service 
Medical Beneﬁ t Scheme. For non-reimbursable health promotion and prevention 
services, unit costs were calculated at a selected hospital for RVU development. To 
test the RVUs, the unit costs calculated by RVU method were compared to those 
computed by conventional micro-costing method. Then, the RVUs were used to cal-
culate standard unit costs of health services. Three district hospitals and three provin-
cial hospitals where met the developed efﬁ ciency criteria were selected for the 
calculation. Total hospital cost including labor, material and capital costs and exclud-
ing pharmacy cost was calculated. Total RVUs were calculated by the summation of 
the multiplication of number of health services provided and its RVU. Total cost was 
divided by the total RVUs resulting in cost per RVU. Finally, unit cost of each service 
was calculated by the multiplication of number of RVUs and cost per RVU. RESULTS: 
This study results in RVUs of 3091 health service items which were classiﬁ ed into 12 
groups. Unit cost of each service classiﬁ ed by types of hospitals was provided. A web-
based standard unit cost list was created and could be accessible to the public. 
CONCLUSIONS: This study developed the ﬁ rst list of standard unit cost of health 
services of district and provincial hospitals in Thailand. The standard unit cost list is 
an important tool for providing cost inputs when performing economic evaluation of 
health interventions and it helps standardize and improve the quality of economic 
evaluation studies in Thailand. 
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OBJECTIVES: The use of statin has been shown to be cost effective in the secondary 
prevention of coronary heart disease and cerebrovascular disease. However, a “treat-
ment gap” exists, whereby many eligible patients do not receive statin therapy. We 
sought to determine the cost-effectiveness of closing this treatment gap in the Austra-
lian healthcare setting. METHODS: Analysis was based on 4-year follow-up data from 
Australian participants of the Reduction of Atherothrombosis for Continued Health 
(REACH) Registry. Subjects were aged 345 years and had established atherothrom-
botic disease, comprising coronary artery disease (CAD), and cerebrovascular (CerVD) 
disease. Decision analysis was applied to compare current coverage with statin against 
a hypothetical situation whereby all subjects were assumed to be treated. Outcomes 
of interest were nonfatal stroke, nonfatal myocardial infraction (MI), and cardiovas-
cular deaths. The relative changes to the risks of these outcomes conferred by statin 
were derived from published meta-analysis. Costs were based on government-reim-
bursed data for 2009. RESULTS: Among the sample of 2768 participants, coverage 
with statin therapy was between 63% and 82%, depending on age group. Over the 
4-year period, 89, 101, and 146 nonfatal strokes, nonfatal MIs, and cardiovascular 
deaths were observed, respectively. Assuming that all subjects had taken statin, the 
predicted equivalent numbers were 85, 96, and 137 respectively. The estimated incre-
mental cost-effectiveness ratio (ICER) for CAD subjects was AUD $45,274 per life-
year gained (LYG). For CerVD subjects, the ICERs were AUD $40,738. Equating to 
numbers needed to treat of 136 and 99.5. Sensitivity analysis showed that the results 
were robust. CONCLUSIONS: The results of this model suggest that for subjects with 
athethrombotic disease, maximizing coverage with statin, in line with evidence-based 
recommendations, represents a cost-effective means of secondary prevention. 
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OBJECTIVES: Patients receiving enoxaparin are at risk of bleeding. However, the 
study of the ﬁ nancial impact of enoxaparin-associated bleeding is limited. This study 
aims to estimate the attributable costs and length of stay (LOS) of patients with 
enoxaparin-associated bleeding (EAB) compared with non-bleeding patients (NB). 
METHODS: We conducted a retrospective cohort study of hospitalized acute coro-
nary syndrome patients who received enoxaparin since January 2006 to February 
2009 in a large University-afﬁ liated hospital. Cost and LOS were compared between 
patients with and without EAB on both univariable and multivariable analyses. In 
multivariable analysis, the attributable cost and LOS were estimated using a multiple 
linear regression with log-transformed model and adjusted by propensity score (PS), 
which was predicted by patient’ characteristics including age, gender, history of bleed-
ing, hypertension, stroke, diabetes, creatinine clearance, and congestive heart failure 
(CHF) at admission. The adjusted means of cost and LOS estimates were retrans-
formed to their natural values using Duan’s smearing estimator. The differences of 
costs and LOS were presented as mean with 95% conﬁ dence intervals. RESULTS: 
Out of 346 patients, 134 (38.7%) experienced enoxaparin-associated bleeding. The 
average age and comorbidities in both groups were similar. However, in EAB group 
had more male than NB group (42% vs. 30%). Based on univariable analyses, the 
attributable cost and LOS of patients with EAB were 68,875 THB ($2152) and 4.2 
days, respectively. Based on PS-adjusted multivariable regression analyses, the cost 
and LOS attributable to EAB was 80,644 THB ($2520) (95% CI: 69,879 ($2184) to 
91,408 ($2857) and 3.4 days (95% CI: 3.0 to 3.7), respectively. CONCLUSIONS: 
Bleeding is associated with increased cost and LOS among enoxaparin users. These 
ﬁ ndings suggest that strategies that reduce the risk of bleeding have the potential 
important reductions in costs of care for enoxaparin users. 
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OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban against enoxaparin 
for prevention of venous thromboembolism (VTE) following total knee replacement 
(TKR) in China. METHODS: An economic model was developed, consisting of three 
modules: prophylaxis, post-prophylaxis, and long-term complications. The ﬁ rst two 
modules were represented using a decision tree while the third module used a Markov 
process. Safety and efﬁ cacy data during prophylaxis were derived from a Phase III inter-
national multi-regional registration trail (RECORD 3). Utility outcomes and the probabil-
ity of long-term events were based on systematic review and published data. Resource use 
related to VTE prevention, treatment and complications was based on clinical guidelines, 
product labels, and interviews conducted in six Tier 3 hospitals in Beijing, Shanghai and 
Guangzhou City. Unit cost data were collected from government pricing bureau and 
presented in 2009 CNY from the health-care system perspective. Costs and outcomes were 
discounted at 3% per annum. Extensive one-way probabilistic sensitivity analyses were 
undertaken. RESULTS: In the base case analyses, rivaroxaban was shown to be domi-
nant compared with enoxaparin. Rivaroxaban was associated with 0.0019 additional 
QALYs per patient while saving an average of CNY 242 per patient over 5 years. 
Costs associated with VTE clinical events were lower in rivaroxaban group (CNY 
581) compared with the enoxaparin group (CNY 1059). Probabilistic sensitivity 
analyses estimated that rivaroxaban had a probability of >90% of being cost-effective 
compared with enoxaparin at a low willingness-to-pay threshold of CNY 20,000 per 
QALY gained. CONCLUSIONS: Compared with enoxaparin, rivaroxaban improved 
patients’ health outcomes and produced overall cost savings in VTE prevention after 
TKR in China. 
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OBJECTIVES: This systematic review was conducted for The New Zealand Ministry 
of Health to summarize recent evidence pertaining to the clinical effectiveness of 
64-slice or higher computed tomography angiography (CTA) in patients with sus-
pected coronary artery disease (CAD). If CTA proves to be a successful diagnostic 
performance measure, it could prevent the application of invasive diagnostic proce-
dures in some patients. This would provide multiple health and cost beneﬁ ts, particu-
larly for under resourced District Health Boards where invasive coronary angiography 
is not always available. METHODS: A systematic method of literature searching and 
selection was employed with searches limited to December 2006 to March 2009. 
Included studies were quality assessed using NHMRC diagnostic levels of evidence 
and a modiﬁ ed QUADAS tool. Individual and pooled diagnostic performance mea-
sures (i.e., sensitivity, speciﬁ city, positive predictive value (PPV), negative predictive 
